Mutations that affect CFTR gating are known to cause CF, including the two most common, ΔF508 and G551D. Although the mechanism remains unclear, evidence suggests the CF-therapeutic Kalydeco increases channel opening by an ATP-independent mechanism after RD phosphorylation9,10. Here, CFTR is linked to cystic fibrosis.